Market Exclusive

Analyst Activity – Royal Bank Of Canada Reiterates Hold on Novelion Therapeutics (NASDAQ:NVLN)

Analyst Ratings For Novelion Therapeutics (NASDAQ:NVLN)

Today, Royal Bank Of Canada reiterated its Hold rating on Novelion Therapeutics (NASDAQ:NVLN) with a price target of $9.00.

There are 2 hold ratings on the stock.

The current consensus rating on Novelion Therapeutics (NASDAQ:NVLN) is Hold (Score: 2.00) with a consensus target price of $9.00 per share, a potential 25.70% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Novelion Therapeutics (NASDAQ:NVLN)
Novelion Therapeutics (NASDAQ:NVLN) has insider ownership of 14.10% and institutional ownership of 78.44%.

Recent Trading Activity for Novelion Therapeutics (NASDAQ:NVLN)
Shares of Novelion Therapeutics closed the previous trading session at with shares trading hands.

Exit mobile version